https://charts.traderzeitung.de/phases/US57777K1060
string(1420) "{"isin":"US57777K1060","name":"MaxCyte Inc","stock_id_xnas":19105665,"stock_id_xnys":null,"generated_at":"2026-08-21 21:10:00","days":[{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.29,"close_at":"2026-08-19 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.4,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":8.5271},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":1.4,"close_at":"2026-08-20 00:54:00","complete":true,"perf_pct":0}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.385,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-1.0714},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.375,"close_at":"2026-08-21 20:58:00","complete":false,"perf_pct":-0.722},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
MaxCyte Aktie News & Nachrichten
Trading-Room

MaxCyte Aktie News & Nachrichten

[WKN: A2AGVE | Symbol: MXCT]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

MaxCyte

MaxCyte Inc. (MXCT): Stephens sieht eine frühen Phase der Investitionen in die Erweiterung der Marktreichweite mit 186 % Kurspotenzial

MaxCyte Inc. (MXCT) ist ein auf Zell-Engineering spezialisiertes Unternehmen, das wegweisende Plattformtechnologien...

  • ‹
  • 1
  • ›
MaxCyte Nachrichtenticker öffnen
MT Newswires 21.07.2026 15:30 Uhr

MaxCyte geht Technologie-Lizenzpartnerschaft mit Genentech ein

09:29 AM EDT, 21.07.2026 (MT Newswires) -- MaxCyte (MXCT) teilte am Dienstag mit, dass das Unternehmen eine Technologie-Lizenzpartnerschaft mit Genent